Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor - PubMed
- ️Sat Jan 01 2011
Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor
Angela Chow et al. J Infect Dis. 2011.
Abstract
Background: Chikungunya virus (CHIKV) infection induces arthralgia. The involvement of inflammatory cytokines and chemokines has been suggested, but very little is known about their secretion profile in CHIKV-infected patients.
Methods: A case-control longitudinal study was performed that involved 30 adult patients with laboratory-confirmed Chikungunya fever. Their profiles of clinical disease, viral load, and immune mediators were investigated.
Results: When patients were segregated into high viral load and low viral load groups during the acute phase, those with high viremia had lymphopenia, lower levels of monocytes, neutrophilia, and signs of inflammation. The high viral load group was also characterized by a higher production of pro-inflammatory cytokines, such as interferon-α and interleukin (IL)-6, during the acute phase. As the disease progressed to the chronic phase, IL-17 became detectable. However, persistent arthralgia was associated with higher levels of IL-6 and granulocyte macrophage colony-stimulating factor, whereas patients who recovered fully had high levels of Eotaxin and hepatocyte growth factor.
Conclusions: The level of CHIKV viremia during the acute phase determined specific patterns of pro-inflammatory cytokines, which were associated with disease severity. At the chronic phase, levels of IL-6, and granulocyte macrophage colony-stimulating factor found to be associated with persistent arthralgia provide a possible explanation for the etiology of arthralgia that plagues numerous CHIKV-infected patients.
Figures

Association of laboratory parameters with viral load. A, Patients were separated into 2 groups according to their viral load: high viral load (HVL; n = 14) and low viral load (LVL; n = 16). Comparisons of C-reactive protein (B), lymphocyte (C), monocyte (D), and neutrophil (E) levels between HVL and LVL groups. Data are presented as mean ± standard error of the mean (SEM). *P < .05; **P < .01; ***P < .001, Mann–Whitney U test, 1-tailed.

Kinetic profiles of immune mediator expression over time during Chikungunya virus (CHIKV) infection. A, Acute phase, median 4 days after illness onset; B; Early convalescent phase, median 10 days after illness onset; C, Late convalescent phase, 4–6 weeks after illness onset; and D, chronic phase, 2–3 months after illness onset. Comparisons between patients with CHIKF and normal healthy control subjects were analyzed using a 1-tailed Mann–Whitney U test. Horizontal dotted lines represent median values for healthy control subjects. Samples from all 30 patients were analyzed for each time. Data are presented as mean ± standard error of the mean (SEM). (*P < .05; **P < .01; ***P < .001).

Patterns of acute phase immune mediators, shown by 2-way hierarchical clustering. Each colored cell in the 3 hit maps represents the relative levels of expression of a particular cytokine in a patient. Green indicates low production, and red indicated high production. The first and second hit maps from the left represent the qualitative cytokine expression profiles of patients in the high viral load (HVL) and low viral load (LVL) groups, respectively. Different disease phases are illustrated: acute phase (median, 4 days after illness onset), early convalescent phase (median, 10 days after illness onset), late convalescent phase (4–6 weeks after illness onset), and chronic phase (2–3 months after illness onset).

Expression of inflammatory mediators during acute Chikungunya virus (CHIKV) infection. Levels of IFN-α, IL-1Ra, IL-6, IL-12, IL-15, IP-10, and MCP-1 in infected patients were compared with those in healthy control subjects with use of the nonparametric, 1-tailed Mann–Whitney U test. Horizontal dotted lines represent median values for healthy control subjects. Data are presented as mean ± standard error of the mean (SEM). (*P < .05; **P < .01; ***P < .001). Different disease phases are illustrated: acute phase (median, 4 days after illness onset), early convalescent phase (median, 10 days after illness onset), late convalescent phase (4–6 weeks after illness onset), and chronic phase (2–3 months after illness onset).

Cytokines implicated in chronic arthropathy. A, Levels of IL-6 and GM-CSF in patients who experienced persistent joint pain, compared with those in persons who made a full recovery at 2–3 months after Illness onset. B, Eotaxin and HGF levels were significantly lower in patients who still had persistent joint pain, compared with those who recovered completely. Horizontal dotted lines represent median values for healthy control subjects. *P < .05, Mann–Whitney U test, 1-tailed.
Comment in
-
Chikungunya fever: focus on peripheral markers of pathogenesis.
Roques P, Gras G. Roques P, et al. J Infect Dis. 2011 Jan 15;203(2):141-3. doi: 10.1093/infdis/jiq026. J Infect Dis. 2011. PMID: 21288810 Free PMC article. No abstract available.
-
Noret M, Herrero L, Rulli N, Rolph M, Smith PN, Li RW, Roques P, Gras G, Mahalingam S. Noret M, et al. J Infect Dis. 2012 Aug 1;206(3):455-7: 457-9. doi: 10.1093/infdis/jis368. Epub 2012 May 25. J Infect Dis. 2012. PMID: 22634878 No abstract available.
Similar articles
-
Ninla-Aesong P, Mitarnun W, Noipha K. Ninla-Aesong P, et al. Viral Immunol. 2019 Dec;32(10):442-452. doi: 10.1089/vim.2019.0064. Epub 2019 Nov 12. Viral Immunol. 2019. PMID: 31718485
-
Poo YS, Nakaya H, Gardner J, Larcher T, Schroder WA, Le TT, Major LD, Suhrbier A. Poo YS, et al. J Virol. 2014 Jun;88(12):6862-72. doi: 10.1128/JVI.03364-13. Epub 2014 Apr 2. J Virol. 2014. PMID: 24696480 Free PMC article.
-
Cytokine levels in patients with chikungunya virus infection.
Chirathaworn C, Poovorawan Y, Lertmaharit S, Wuttirattanakowit N. Chirathaworn C, et al. Asian Pac J Trop Med. 2013 Aug;6(8):631-4. doi: 10.1016/S1995-7645(13)60108-X. Asian Pac J Trop Med. 2013. PMID: 23790334
-
Dupuis-Maguiraga L, Noret M, Brun S, Le Grand R, Gras G, Roques P. Dupuis-Maguiraga L, et al. PLoS Negl Trop Dis. 2012;6(3):e1446. doi: 10.1371/journal.pntd.0001446. Epub 2012 Mar 27. PLoS Negl Trop Dis. 2012. PMID: 22479654 Free PMC article. Review.
-
Chikungunya Virus-Induced Arthritis: Role of Host and Viral Factors in the Pathogenesis.
Amdekar S, Parashar D, Alagarasu K. Amdekar S, et al. Viral Immunol. 2017 Dec;30(10):691-702. doi: 10.1089/vim.2017.0052. Epub 2017 Sep 14. Viral Immunol. 2017. PMID: 28910194 Review.
Cited by
-
Pathogenicity and virulence of chikungunya virus.
Freppel W, Silva LA, Stapleford KA, Herrero LJ. Freppel W, et al. Virulence. 2024 Dec;15(1):2396484. doi: 10.1080/21505594.2024.2396484. Epub 2024 Sep 1. Virulence. 2024. PMID: 39193780 Free PMC article. Review.
-
Sepúlveda-Delgado J, Vera-Lastra OL, Trujillo-Murillo K, Canseco-Ávila LM, Sánchez-González RA, Gómez-Cruz O, Lugo-Trampe A, Fernández-Salas I, Danis-Lozano R, Contreras-Contreras A, Mendoza-Torres A, Domínguez-Arrevillaga S, Mena-Vela BA, Ocaña-Sibilla M, Ramirez-Valdespino JC, Jara LJ. Sepúlveda-Delgado J, et al. Clin Rheumatol. 2017 Mar;36(3):695-699. doi: 10.1007/s10067-016-3419-2. Epub 2016 Sep 28. Clin Rheumatol. 2017. PMID: 27680539
-
Nakaya HI, Gardner J, Poo YS, Major L, Pulendran B, Suhrbier A. Nakaya HI, et al. Arthritis Rheum. 2012 Nov;64(11):3553-63. doi: 10.1002/art.34631. Arthritis Rheum. 2012. PMID: 22833339 Free PMC article.
-
Clinical markers of post-Chikungunya chronic inflammatory joint disease: A Brazilian cohort.
Lázari CDS, Ramundo MS, Ten-Caten F, Bressan CS, de Filippis AMB, Manuli ER, de Moraes I, Pereira GM, Côrtes MF, Candido DDS, Gerber AL, Guimarães AP, Faria NR, Nakaya HI, Vasconcelos ATR, Brasil P, Paranhos-Baccalà G, Sabino EC. Lázari CDS, et al. PLoS Negl Trop Dis. 2023 Jan 6;17(1):e0011037. doi: 10.1371/journal.pntd.0011037. eCollection 2023 Jan. PLoS Negl Trop Dis. 2023. PMID: 36608155 Free PMC article.
-
Guerrero-Arguero I, Høj TR, Tass ES, Berges BK, Robison RA. Guerrero-Arguero I, et al. PLoS One. 2020 Mar 12;15(3):e0230328. doi: 10.1371/journal.pone.0230328. eCollection 2020. PLoS One. 2020. PMID: 32163514 Free PMC article.
References
-
- Bonn D. How did Chikungunya reach the Indian Ocean? Lancet Infect Dis. 2006;6:543. - PubMed
-
- Enserink M. Tropical disease follows mosquitoes to Europe. Science. 2007;317:1485. - PubMed
-
- Leelarasamee A, Chupaprawan C, Chenchittikul M, Udompanthurat S. Etiologies of acute undifferentiated febrile illness in Thailand. J Med Assoc Thai. 2004;87:464–72. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials